Synopsis
Synopsis
0
JDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. (2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
2. 1-pyrrolidineacetamide, Alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-
3. 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
4. Briviact
5. Ucb 34714
6. Ucb-34714
7. Ucb34714
1. 357336-20-0
2. Briviact
3. Ucb-34714
4. Ucb 34714
5. Ucb34714
6. 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
7. (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
8. (2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
9. U863jgg2ia
10. Rikelta
11. Brivaracetam [usan:inn]
12. Unii-u863jgg2ia
13. Compound 83alpha
14. 1-pyrrolidineacetamide, Alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-
15. Brivaracetam 97%
16. Briviact (tn)
17. Brivaracetam [mi]
18. Brivaracetam [inn]
19. Brivaracetam [jan]
20. Brivaracetam [usan]
21. Brivaracetam [mart.]
22. Brivaracetam [who-dd]
23. Schembl122081
24. Brivaracetam (jan/usan/inn)
25. Chembl607400
26. Gtpl9041
27. Dtxsid00905081
28. Chebi:133013
29. Brivaracetam [orange Book]
30. Ex-a2748
31. Zinc3979899
32. Bdbm50422531
33. Mfcd25976668
34. Akos027324306
35. Ccg-266666
36. Cs-3418
37. Db05541
38. Ncgc00390779-02
39. Ac-29289
40. As-35277
41. Bb161996
42. Hy-14449
43. D08879
44. Q408099
45. (s)-2-((r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
46. (2s)-2-((4r)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide
47. (2s)-2-((4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl) Butanamide
48. 1-pyrrolidineacetamide, .alpha.-ethyl-2-oxo-4-propyl (.alpha.s,4r)-
Molecular Weight | 212.29 g/mol |
---|---|
Molecular Formula | C11H20N2O2 |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 5 |
Exact Mass | 212.152477885 g/mol |
Monoisotopic Mass | 212.152477885 g/mol |
Topological Polar Surface Area | 63.4 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 253 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
FDA Label
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Treatment of epilepsy with partial-onset seizures, Treatment of neonatal seizures
Treatment of neonatal seizures, Treatment of paediatric epilepsy syndromes
Treatment of epilepsy with partial-onset seizures
Brivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AX23
N03AX23
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX23 - Brivaracetam
Absorption
Nearly 100% oral bioavailability.
Route of Elimination
\>95% excreted in urine with <10% of the parent compound unchanged. <1% excreted in feces.
Volume of Distribution
0.5L/kg.
Clearance
CL/F of 0.7-1.07 mL/min kg. Clearance is primarily metabolic with less than 10% of the parent drug excreted unchanged.
Primarily metabolized by hydrolysis of the acetamide moeity to form a carboxylic acid metabolite. Another metabolite is created via oxidation of the propyl side chain by CYP2C8 as well as CYP3A4, CYP2C19, and CYP2B6. Some conjugation with glucuronic acid and taurine account for a small amount of metabolism.
7-8h.
The precise mechanism of brivaracetam's anti-epileptogenic activity is unknown.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36655
Submission : 2022-01-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-02-19
Pay. Date : 2020-01-21
DMF Number : 34511
Submission : 2020-01-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-04-15
Pay. Date : 2020-03-02
DMF Number : 34398
Submission : 2020-01-17
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-03-20
Pay. Date : 2020-01-30
DMF Number : 34569
Submission : 2020-02-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-03-23
Pay. Date : 2020-02-18
DMF Number : 34402
Submission : 2019-12-09
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-11-05
Pay. Date : 2019-09-26
DMF Number : 33709
Submission : 2019-03-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-03-23
Pay. Date : 2020-02-19
DMF Number : 34585
Submission : 2020-02-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36649
Submission : 2022-04-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36304
Submission : 2021-09-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36409
Submission : 2021-12-26
Status : Active
Type : II
Certificate Number : CEP 2024-061 - Rev 00
Status : Valid
Issue Date : 2024-08-12
Type : Chemical
Substance Number : 3139
Date of Issue : 2022-08-11
Valid Till : 2025-06-26
Written Confirmation Number : WC-0054
Address of the Firm : Block No. 82/B, ECP Road, At & Post. Karakhadi, Tal-Padra, City Karakhadi -39145...
Date of Issue : 2023-03-21
Valid Till : 2025-07-28
Written Confirmation Number : WC-0186
Address of the Firm : Sy. No. 10/G-1, Gaddapotharam Village, Jinnaram Mandal, Sangareddy, Pin-502319, ...
Date of Issue : 2022-11-18
Valid Till : 2025-09-30
Written Confirmation Number : WC-0455
Address of the Firm : Sy No 14, IDA Gaddapotharm, Jinnaram, Sangareddy (DT), TS-502319
Date of Issue : 2021-07-20
Valid Till : 2022-08-15
Written Confirmation Number : WC-0225A10
Address of the Firm : 43-45 KIADB Bommasandra Industrial Area, 4th Phase, Anekal Taluk, Bangalore-560 ...
Date of Issue : 2022-09-30
Valid Till : 2025-08-04
Written Confirmation Number : WC-0127
Address of the Firm : A1/B, SIPCOT Industrial Complex, Kudikadu, Cuddalore-607 005
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Brivaracetam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brivaracetam, including repackagers and relabelers. The FDA regulates Brivaracetam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brivaracetam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Brivaracetam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Brivaracetam supplier is an individual or a company that provides Brivaracetam active pharmaceutical ingredient (API) or Brivaracetam finished formulations upon request. The Brivaracetam suppliers may include Brivaracetam API manufacturers, exporters, distributors and traders.
click here to find a list of Brivaracetam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Brivaracetam DMF (Drug Master File) is a document detailing the whole manufacturing process of Brivaracetam active pharmaceutical ingredient (API) in detail. Different forms of Brivaracetam DMFs exist exist since differing nations have different regulations, such as Brivaracetam USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Brivaracetam DMF submitted to regulatory agencies in the US is known as a USDMF. Brivaracetam USDMF includes data on Brivaracetam's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Brivaracetam USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Brivaracetam suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Brivaracetam Drug Master File in Korea (Brivaracetam KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Brivaracetam. The MFDS reviews the Brivaracetam KDMF as part of the drug registration process and uses the information provided in the Brivaracetam KDMF to evaluate the safety and efficacy of the drug.
After submitting a Brivaracetam KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Brivaracetam API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Brivaracetam suppliers with KDMF on PharmaCompass.
A Brivaracetam CEP of the European Pharmacopoeia monograph is often referred to as a Brivaracetam Certificate of Suitability (COS). The purpose of a Brivaracetam CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Brivaracetam EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Brivaracetam to their clients by showing that a Brivaracetam CEP has been issued for it. The manufacturer submits a Brivaracetam CEP (COS) as part of the market authorization procedure, and it takes on the role of a Brivaracetam CEP holder for the record. Additionally, the data presented in the Brivaracetam CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Brivaracetam DMF.
A Brivaracetam CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Brivaracetam CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Brivaracetam suppliers with CEP (COS) on PharmaCompass.
A Brivaracetam written confirmation (Brivaracetam WC) is an official document issued by a regulatory agency to a Brivaracetam manufacturer, verifying that the manufacturing facility of a Brivaracetam active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Brivaracetam APIs or Brivaracetam finished pharmaceutical products to another nation, regulatory agencies frequently require a Brivaracetam WC (written confirmation) as part of the regulatory process.
click here to find a list of Brivaracetam suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Brivaracetam as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Brivaracetam API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Brivaracetam as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Brivaracetam and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Brivaracetam NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Brivaracetam suppliers with NDC on PharmaCompass.
Brivaracetam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brivaracetam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brivaracetam GMP manufacturer or Brivaracetam GMP API supplier for your needs.
A Brivaracetam CoA (Certificate of Analysis) is a formal document that attests to Brivaracetam's compliance with Brivaracetam specifications and serves as a tool for batch-level quality control.
Brivaracetam CoA mostly includes findings from lab analyses of a specific batch. For each Brivaracetam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brivaracetam may be tested according to a variety of international standards, such as European Pharmacopoeia (Brivaracetam EP), Brivaracetam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brivaracetam USP).
LOOKING FOR A SUPPLIER?